背景:迫切需要新的化学疗法来治疗由耐药菌株引起的念珠菌感染。方法:与Mn(II)络合的161,10-菲咯啉(phen)/1,10-菲咯啉-5,6-二酮/二羧酸酯的作用,针对十种不同的念珠菌物种评估了Cu(II)和Ag(I)。结果:白色念珠菌的增殖,都柏林念珠菌,念珠菌,光滑念珠菌,念珠菌,Kefyr念珠菌,克鲁斯念珠菌,念珠菌,近扁平念珠菌和热带念珠菌被六种Cu(II)中的三种(MIC1.52-21.55μM)抑制,三个Ag(I)(MIC0.11-12.74μM)和七个Mn(II)(MIC0.40-38.06μM)络合物中的七个。在这些[Mn2(oda)(phen)4(H2O)2][Mn2(oda)(phen)4(oda)2].4H2O中,其中oda=辛酸,表现出有效的生长抑制(MIC0.4-3.25μM),有利的活性指数,对Vero细胞的低毒性和良好/优异的选择性指数(46.88-375)。结论:[Mn2(oda)(phen)4(H2O)2][Mn2(oda)(phen)4(oda)2].4H2O代表了新兴的有希望的化疗选择,医学相关和耐药的念珠菌物种。
念珠菌是广泛存在的真菌,可引起人类多种感染,其中一些对现有抗真菌药物表现出耐药性。因此,有必要发现新的治疗这些临床相关的人类感染。络合物是含有金属离子成分的化合物,以其抗微生物特性而闻名,包括抗真菌活性。在本研究中,我们研究了16种新型复合物对10种医学相关念珠菌的影响,包括一些对临床常用抗真菌药物具有抗性的菌株。我们的发现表明,所有含锰和银金属的配合物有效地抑制了所有测试的念珠菌的生长,尽管程度不同。与传统抗真菌剂相比,这些复合物中的一些表现出优异的抗真菌活性和对哺乳动物细胞的低毒性。如氟康唑。总之,这些新的复合物有望成为治疗真菌感染的潜在新方法,尤其是那些由耐药念珠菌菌株引起的。
Background: New chemotherapeutics are urgently required to treat Candida infections caused by drug-resistant strains. Methods: The effects of 16 1,10-phenanthroline (phen)/1,10-phenanthroline-5,6-dione/dicarboxylate complexed with Mn(II), Cu(II) and Ag(I) were evaluated against ten different Candida species. Results: Proliferation of Candida albicans, Candida dubliniensis, Candida famata, Candida glabrata, Candida guilliermondii, Candida kefyr, Candida krusei, Candida lusitaniae, Candida parapsilosis and Candida tropicalis was inhibited by three of six Cu(II) (MICs 1.52-21.55 μM), three of three Ag(I) (MICs 0.11-12.74 μM) and seven of seven Mn(II) (MICs 0.40-38.06 μM) complexes. Among these [Mn2(oda)(phen)4(H2O)2][Mn2(oda)(phen)4(oda)2].4H2O, where oda = octanedioic acid, exhibited effective growth inhibition (MICs 0.4-3.25 μM), favorable activity indexes, low toxicity against Vero cells and good/excellent selectivity indexes (46.88-375). Conclusion: [Mn2(oda)(phen)4(H2O)2][Mn2(oda)(phen)4(oda)2].4H2O represents a promising chemotherapeutic option for emerging, medically relevant and drug-resistant Candida species.
Candida species are widespread fungi that can cause a variety of infections in humans, and some of them exhibit resistance profile to existing antifungal drugs. Consequently, it is imperative to discover novel treatments for these clinically relevant human infections. Complexes are chemical compounds containing metal ion components that are well-known for their antimicrobial properties, including antifungal activity. In the present study, we investigated the effects of 16 novel complexes against ten medically relevant Candida species, including some strains resistant to commonly used clinical antifungals. Our findings revealed that all complexes containing manganese and silver metals effectively inhibited the growth of all Candida species tested, albeit to varying extents. Some of these complexes exhibited superior antifungal activity and lower toxicity to mammalian cells compared to traditional antifungals, such as fluconazole. In conclusion, these new complexes hold promise as a potential novel approach for treating fungal infections, especially those caused by drug-resistant Candida strains.